Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
1999-07-13
2002-04-09
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C514S781000
Reexamination Certificate
active
06368616
ABSTRACT:
This application is a 371 application of International Application No. PCT/JP98/00108 filed Jan. 14, 1998, which is ased on Japanese Priority Application No. 9-019664 filed Jan. 16, 1997.
1. Field of the Invention
The present invention relates to a stabilized aqueous suspension of loteprednol etabonate having antiinflammatory and antialletgic activities for use as nasal drops.
2. Background of the Invention
Loteprednol etabonate is a synthetic adrenocortical hormone having excellent antiinflammatory and antiallergic activities, and because of those activities coupled with a low dermal (mucosal) irritation potential and a low risk for side effects, this compound is expected to be of value as a drug for external application, e.g. an ointment or a liquid.
However, since loteprednol etabonate is substantially insoluble in water, it has to be provided in the form of a suspension as far as a liquid dosage form for external application is concerned. Heretofore, as a suspending agent-stabilizer for such a water-insoluble (inclusive of hardly water-soluble) drug, methylcellulose (MC), hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose sodium (CMC-Na), or polyvinylpyrrolidone (PVP), for instance, has been generally employed. As far as loteprednol etabonate is concerned, however, none of said MC, HPMC, CMC-Na, and PVP in its usual formulating amount is capable of providing sufficiently stabilized suspensions. Thus, if such a suspension is allowed to stand for a long time, e.g. 3 months or longer, particles of loteprednol etabonate undergo aggregation and precipitation to form deposits on the container bottom and side walls and once this occurs, the original condition immediately after preparation cannot be reestablished even if the container is shaken or swirled vigorously. Of course, the concentration of the active ingredient in the suspension will be deviating from the concentration immediately after preparation. Furthermore, when the dosage form is nasal drops, the suspension is provided in the conventional nasal sprayer but the aggregation and deposition of particles take place in the nozzle part of the quantitative delivery pump to cause a failure to deliver the designed quantity or clogging of the nozzle orifices.
Therefore, how an aqueous suspension of loteprednol etabonate could be kept stable over a long time has been an important question to be answered.
From the above viewpoint, a stable aqueous suspension of loteprednol etabonate has been proposed by WO 95/11669. However, when the suspension is administered to a nasal cavity, it runs down from the nasal foramen because of its low viscosity less than 80 centipoise. Therefore, the suspension has drawbacks that its retention time is too short to achieve pharmaceutical effect and that the feeling-of-use is not good.
SUMMARY OF THE INVENTION
The inventor of the present invention explored the possibility of stabilizing an aqueous suspension of loteprednol etabonate and of improving intranasal retention of the active ingredients and the feeling-of-use using thickeners including cellulose derivatives such as methylcellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, etc., synthetic macromolecular compounds such as polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, etc., and saccharides such as sorbitol, mannitol, sucrose, etc.; cationic surfactants including quaternary ammonium salts; anionic surfactants including alkylsulfates; and nonionic surfactants including polysorbate 80, polyoxyethylene hydrogenated castor oil, etc. As a result, they discovered that microcrystalline cellulose carmellose sodium is not only highly effective in stabilizing a suspension of loteprednol etabonate but also has a low dermal (mucosal) irritation potential, a favorable feeling of use, and the property to enhance the muscosal retention of the active ingredient and, based on the finding, have developed the present invention. The present invention, therefore, is directed to:
(1) an aqueous suspension for nasal administration which comprises loteprednol etabonate and microcrystalline cellulose carmellose sodium;
(2) The aqueous suspension (1), which comprises 0.05-3 w/w % of loteprednol etabonate and 0.5-10 w/w % of microcrystalline cellulose carmellose sodium;
(3) The aqueous suspension (1), which comprises 0.1-1.5 w/w % of loteprednol etabonate and 1-5 w/w % of microcrystalline cellulose carmellose sodium;
(4) A method of treating inflammation or allergy which comprises administering an effective amount of the aqueous suspension for nasal administration comprising loteprednol etabonate and microcryatalline cellulose carmellose sodium to nasal mucosa; and
(5) The method according to (4), wherein the aqueous suspension for nasal administration comprises 0.05-3 w/w % of loteprednol etabonate and 0.5-10 w/w % of microcrystalline cellulose carmellose sodium.
DETAILED DESCRIPTION OF THE INVENTION
The concentration of loteprednol etabonate in the aqueous suspension for nasal administration according to the present invention is preferably 0.05-3 w/w % and more preferably 0.1-1.5 w/w %.
Meanwhile, microcrystalline cellulose carmellose sodium is generally a mixture containing not less than 80 weight % of crystalline cellulose and 9-13 weight % of carmellose sodium. Though it depends on other additives present, its concentration in the aqueous suspension is preferably 0.5-10 w/w % and more preferably 1-5 w/w %.
The aqueous suspension for nasal administration according to the present invention may contain, in addition to loteprednol etabonate, one or more other active substances such as a nonsteroidal antiinflammatory agent, e.g. mefenamic acid, an antihistaminic, e.g. clemastine fumarate, terfenadine, chlotpheniramine maleate, diphenhydramine hydrochloride, etc., an antiallergic agent such as tranilast, sodium cromoglycate, ketotifen fumarate, etc., an antibiotic, e.g. erythromycin, tetracycline, etc., and/or an antimicrobial agent, e.g. sulfamethizole, sulfamethoxazole, sulfisoxazole, etc., each in a suitable amount.
The aqueous suspension for nasal administration according to the present invention may further contain other pharmacologically active substances, such as a vasoconstrictor, a surface anesthetic, etc., in suitable amounts. The vasoconstrictor includes but is not limited to naphazoline nitrate and phenylephrine hydrochloride. The surface anesthetic includes but is not limited to lidocaine, lidocaine hydrochloride, and mepivacaine hydrochloride. These pharmacologically active substances are used in a proportion of generally 0.01-10 w/w % and preferably 0.05-5 w/w %.
The aqueous suspension for nasal administration according to the present invention may contain various additives which are broadly used in nasal drops in general. Among such additives are preservatives, isotonizing agents, buffers, stabilizers, pH control agents, and suspending agents. The preservative that can be used includes parabens (e.g. methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, etc.), invert soaps (e.g. benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, cetylpyridinium chloride, etc.), alcohol derivatives (e.g. chlorobutanol, phenethyl alcohol, etc.), organic acids (e.g. dehydroacetic acid, sorbic acid, etc.), phenols (e.g. p-chloromethoxyphenol, p-chlorometacresol, etc.), and organomercury compounds (e.g. thimerosal, phenylmercury nitrate, nitromersol, etc.). The isotonizing agent includes but is not limited to glycerin, propylene glycol, sorbitol, and mannitol. The buffer that can be used includes boric acid, phosphoric acid, acetic acid, and amino acids, among others. The stabilizer includes antioxidants (e.g. dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), propyl gallate, etc.), and chelating agents (edetic acid, citric acid, etc.). The pH control agent includes hydrochloric acid, acetic acid, sodium hydroxide, phosphoric acid, citric acid, etc. As the suspending agent, various surfactants (nonionic surfactants such as polysorbate 80, polyoxyethylene hydrogenated castor oil, tyloxapol; cationic surfactant
Azpuru Carlos A.
Senju Pharmaceutical Co. Ltd.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Aqueous suspension for nasal administration of loteprednol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aqueous suspension for nasal administration of loteprednol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aqueous suspension for nasal administration of loteprednol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2925701